CytomX reports 2025 revenue $76.2M, down 45% YoY; cash $137.1M; Astellas collaboration ends

CytomX Therapeutics, Inc.

Revenue $76.2M (down from $138.1M in 2024) on completion of BMS collaboration and lower collaboration milestones.
Cash and investments $137.1M at Dec 31, 2025, up from $100.6M; cash runway to Q2 2027.
Astellas terminated preclinical alliance effective Q2 2026; research with BMS, Amgen, Regeneron, Moderna continues.
Varseta-M Phase 1 data positive; FDA alignment for potential registrational trial in late-line CRC targeted mid-2026.
CX-801 Phase 1 combo with KEYTRUDA in melanoma initial proof-of-concept data expected by end of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.